These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38765324)

  • 21. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.
    Teo HM; Smith TJ; Joseph SS
    Ther Clin Risk Manag; 2021; 17():1219-1230. PubMed ID: 34858025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early experience with teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Kikkawa DO; Korn BS
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100744. PubMed ID: 32462101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
    Hoang TD; Nguyen NT; Chou E; Shakir MK
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion.
    Kelly DA; Turbin RE
    Am J Ophthalmol Case Rep; 2024 Jun; 34():102031. PubMed ID: 38487336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.
    Bocklud BE; Fakhre W; Murphy B; Maddox K; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
    Cureus; 2023 Aug; 15(8):e43878. PubMed ID: 37746376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
    Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
    Subramanian PS; Cho RI; Kahana A
    Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease.
    Ting MAJ; Topilow NJ; Ediriwickrema LS; Yoon JS; Liu CY; Korn BS; Kikkawa DO
    Orbit; 2024 Apr; 43(2):222-230. PubMed ID: 37978819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.
    Sears CM; Wang Y; Bailey LA; Turbin R; Subramanian PS; Douglas R; Cockerham K; Kossler AL
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101111. PubMed ID: 34113737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
    Girnita L; Smith TJ; Janssen JAMJL
    J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teprotumumab in thyroid eye disease.
    Goldberg H; Malik AI
    Saudi J Ophthalmol; 2024; 38(1):29-33. PubMed ID: 38628412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
    Ho TC; Maamari RN; Kossler AL; Sears CM; Freitag SK; Reshef ER; Shinder R; Rootman DB; Diniz SB; Kahana A; Schlachter D; Do TH; Kally P; Turner S; Mokhtarzadeh A; Harrison AR; Hwang CJ; Kim HJ; Avila SA; Thomas DA; Magazin M; Wester ST; Lee WW; Clauss KD; Holds JB; Sniegowski M; Compton CJ; Briggs C; Malik AI; Lucarelli MJ; Burkat CN; Patel LG; Couch SM
    Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):150-155. PubMed ID: 36095848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.